Korean J Med.  2015 Aug;89(2):229-232. 10.3904/kjm.2015.89.2.229.

Febuxostat for the Treatment of Chronic Tophaceous Gout in a Patient on Continuous Ambulatory Peritoneal Dialysis

Affiliations
  • 1Department of Internal Medicine, Bong Seng Memorial Hospital, Busan, Korea. j-seok@hanmail.net

Abstract

Hyperuricemic patients with gouty arthritis or tophi, a serum uric acid concentration of 8.0 mg/dL or higher, and complications should be treated with urate-lowering drugs. Conventionally, allopurinol is used to treat hyperuricemia and gout, but it is necessary to adjust the dosage according to the degree of renal impairment. Uncommonly, allopurinol may have severe or fatal side effects. The non-purine xanthine oxidase inhibitor febuxostat undergoes hepatic metabolism and may require less dose adjustment in association with renal function. It is considered to be an alternative treatment for hyperuricemic patients with chronic kidney disease. Our experience suggests that low-dose febuxostat is a promising alternative to allopurinol for the treatment of gouty arthritis or tophi in peritoneal dialysis patients.

Keyword

Chronic kidney failure; Tophi; Febuxostat

MeSH Terms

Allopurinol
Arthritis, Gouty
Gout*
Humans
Hyperuricemia
Kidney Failure, Chronic
Metabolism
Peritoneal Dialysis
Peritoneal Dialysis, Continuous Ambulatory*
Renal Insufficiency, Chronic
Uric Acid
Xanthine Oxidase
Febuxostat
Allopurinol
Uric Acid
Xanthine Oxidase
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr